HK Stock Market Move | BIOHEART-B(02185) continues to rise by over 13%, with frequent catalytic events in the RDN this year. Institutions say that the commercialization of hundreds of peaceful hearts will soon accelerate.

BIOHEART-B (02185) rose by over 10%, as of the time of writing, it has risen by 13.5% to 8.83 Hong Kong dollars, with a trading volume of 1.06 billion Hong Kong dollars. Huafu Securities released a research report stating that in March 2025, Boston Scientific acquired SoniVie for a total of 600 million US dollars, actively entering the RDN track; in August, the American College of Cardiology and the American Heart Association updated the hypertension treatment guidelines and included RDN in the guidelines as a IIb level recommendation; the RDN national coverage decision proposed by the US Medicare (CMS) in July, if passed, will greatly accelerate clinical promotion and application. The bank pointed out that Renal denervation (RDN) is a new therapy for uncontrolled and refractory hypertension devices. According to Zhoushi Consulting, it is estimated that the annual market size of RDN in China will exceed 10 billion RMB by 2032. The bank pointed out that Bai Xin'an Iberis RDN system is the only globally approved and marketed system that can be used for both transradial artery (TRA) and transfemoral artery RDN, with significant first-mover advantage. It has already formed a heavy strategic cooperation with Yuanda Health and Blue Sail Bashenda in many countries and regions overseas. Germany and France have included Iberis RDN in medical insurance, and it is currently the starting point for Baisinan's commercial acceleration.